Novo Nordisk A/S has signed an agreement with Janssen Biotech, Inc. under which Janssen will acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement were disclosed.

The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the US Department of Justice Antitrust Division and the US Federal Trade Commission.

Source: Novo Nordisk